Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS

Patrick Blin, Caroline Dureau-Pournin, Jacques Bénichou, Yves Cottin, Patrick Mismetti, Abdelilah Abouelfath, Regis Lassalle, Cécile Droz, Nicholas Moore

Open source

DOI: 10.1007/s40256-021-00517-2
Published: 2021-12-21
Container: American Journal of Cardiovascular Drugs
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40256-021-00517-2,
  title = {Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS},
  author = {Patrick Blin and Caroline Dureau-Pournin and Jacques Bénichou and Yves Cottin and Patrick Mismetti and Abdelilah Abouelfath and Regis Lassalle and Cécile Droz and Nicholas Moore},
  year = {2021},
  journal = {American Journal of Cardiovascular Drugs},
  doi = {10.1007/s40256-021-00517-2},
  url = {https://doi.org/10.1007/s40256-021-00517-2}
}

RIS

TY  - JOUR
TI  - Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS
AU  - Patrick Blin
AU  - Caroline Dureau-Pournin
AU  - Jacques Bénichou
AU  - Yves Cottin
AU  - Patrick Mismetti
AU  - Abdelilah Abouelfath
AU  - Regis Lassalle
AU  - Cécile Droz
AU  - Nicholas Moore
PY  - 2021
JO  - American Journal of Cardiovascular Drugs
DO  - 10.1007/s40256-021-00517-2
UR  - https://doi.org/10.1007/s40256-021-00517-2
ER  -

APA

Blin, P., Dureau-Pournin, C., Bénichou, J., Cottin, Y., Mismetti, P., Abouelfath, A., Lassalle, R., Droz, C., & Moore, N. (2021). Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-021-00517-2

Source records

crossref · retrieved 2026-09-26T05:04:03.653Z